WO2007124544A1 - Inhibiteurs de l'intégrase du vih1 - Google Patents

Inhibiteurs de l'intégrase du vih1 Download PDF

Info

Publication number
WO2007124544A1
WO2007124544A1 PCT/AU2007/000559 AU2007000559W WO2007124544A1 WO 2007124544 A1 WO2007124544 A1 WO 2007124544A1 AU 2007000559 W AU2007000559 W AU 2007000559W WO 2007124544 A1 WO2007124544 A1 WO 2007124544A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
heteroaryl
mmol
oaryl
Prior art date
Application number
PCT/AU2007/000559
Other languages
English (en)
Inventor
Neil Choi
John Joseph Deadman
William Issa
Eric Dale Jones
Katherine Macfarlane
David Ian Rhodes
Original Assignee
Avexa Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2006902227A external-priority patent/AU2006902227A0/en
Application filed by Avexa Limited filed Critical Avexa Limited
Publication of WO2007124544A1 publication Critical patent/WO2007124544A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • X is selected from -O, -S, -S(O)-, -S(O 2 )-, and -NR 6 -;
  • R 3 is selected from the group consisting of cyano, -C(O)NR 7 Rs, -CH 2 NR 7 R 8 , and CO 2 R 9 ;
  • Example 4 The procedure described in Example 4 was adapted to prepare 2-cyanomethoxy-4-furan-2-yl- 6-thiophen-2-yl-nicotinonitrile.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention décrit une méthode de traitement ou de prophylaxie d'une infection virale chez un sujet, comprenant l'administration audit sujet d'une dose efficace d'un composé de formule (I) ou d'un dérivé, sel ou pro-médicament pharmaceutiquement acceptable de celui-ci. L'invention concerne également des composés de formule (I).
PCT/AU2007/000559 2006-04-28 2007-04-30 Inhibiteurs de l'intégrase du vih1 WO2007124544A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2006902227 2006-04-28
AU2006902227A AU2006902227A0 (en) 2006-04-28 Integrase inhibitor

Publications (1)

Publication Number Publication Date
WO2007124544A1 true WO2007124544A1 (fr) 2007-11-08

Family

ID=38654992

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU2007/000559 WO2007124544A1 (fr) 2006-04-28 2007-04-30 Inhibiteurs de l'intégrase du vih1

Country Status (1)

Country Link
WO (1) WO2007124544A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087212A2 (fr) * 2008-01-11 2009-07-16 Novartis Ag Composés organiques
WO2017200902A1 (fr) * 2016-05-16 2017-11-23 Biotheryx, Inc. Pyridinethiones, compositions pharmaceutiques les contenant, et leur utilisation thérapeutique dans le traitement d'une maladie inflammatoire, neurodégénérative ou d'origine immunologique
US9844218B2 (en) 2013-06-13 2017-12-19 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
US10207995B2 (en) 2013-06-13 2019-02-19 Monsanto Technology Llc Acetyl CoA carboxylase modulators

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124678A1 (en) * 2001-05-04 2005-06-09 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050124678A1 (en) * 2001-05-04 2005-06-09 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] accession no. STN Database accession no. (2005:497502) *
DATABASE REGISTRY [online] 10 April 2001 (2001-04-10), accession no. STN *
DATABASE REGISTRY [online] 25 July 2001 (2001-07-25), accession no. STN *
DATABASE REGISTRY [online] 28 July 2006 (2006-07-28), accession no. STN *
DATABASE REGISTRY [online] 6 March 2003 (2003-03-06), accession no. STN *
DATABASE REGISTRY [online] 9 August 2002 (2002-08-09), accession no. STN *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009087212A2 (fr) * 2008-01-11 2009-07-16 Novartis Ag Composés organiques
WO2009087212A3 (fr) * 2008-01-11 2009-09-24 Novartis Ag Composés organiques
JP2011509277A (ja) * 2008-01-11 2011-03-24 ノバルティス アーゲー ピリジン誘導体
AU2009203681B2 (en) * 2008-01-11 2012-08-16 Novartis Ag Pyridine derivatives
US8343966B2 (en) 2008-01-11 2013-01-01 Novartis Ag Organic compounds
US9844218B2 (en) 2013-06-13 2017-12-19 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
US10207995B2 (en) 2013-06-13 2019-02-19 Monsanto Technology Llc Acetyl CoA carboxylase modulators
US10548313B2 (en) 2013-06-13 2020-02-04 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
US10995070B2 (en) 2013-06-13 2021-05-04 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
US11375716B2 (en) 2013-06-13 2022-07-05 Monsanto Technology Llc Acetyl-CoA carboxylase modulators
WO2017200902A1 (fr) * 2016-05-16 2017-11-23 Biotheryx, Inc. Pyridinethiones, compositions pharmaceutiques les contenant, et leur utilisation thérapeutique dans le traitement d'une maladie inflammatoire, neurodégénérative ou d'origine immunologique
CN109476600A (zh) * 2016-05-16 2019-03-15 拜欧赛里克斯公司 吡啶硫酮、其药物组合物及其用于治疗增殖性、炎症性、神经变性或免疫-介导的疾病的治疗用途
US10233153B2 (en) 2016-05-16 2019-03-19 Biotheryx, Inc. Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease
US10654805B2 (en) 2016-05-16 2020-05-19 Biotheryx, Inc. Pyridinethiones, pharmaceutical compositions thereof, and their therapeutic use for treating a proliferative, inflammatory, neurodegenerative, or immune-mediated disease

Similar Documents

Publication Publication Date Title
JP6828131B2 (ja) 新規の二環式ブロモドメイン阻害剤
JP4523281B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用なヒドロキシナフチリジノンカルボキサミド類
JP5680146B2 (ja) Ｃｒｔｈ２受容体拮抗薬としての複素環化合物
EP2114903B1 (fr) Pyrimidinones bicycliques et utilisations de celles-ci
CA2409743C (fr) Derives de pyrrolopyridinone substitues utiles en tant qu'inhibiteurs de la phosphodiesterase
WO2007124546A1 (fr) Inhibiteurs de l'intégrase-3
JP5743901B2 (ja) 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
JP2022514571A (ja) 二環式誘導体
KR20040041178A (ko) 당뇨병 치료제로서 1,8-나프티리딘 유도체
JPWO2005047286A1 (ja) スピロ複素環化合物
KR20090106604A (ko) 축합 피리딘 화합물
JP2012521428A (ja) 疼痛治療用のｐ２ｘ３受容体アンタゴニスト
JP2010523725A (ja) 皮膚疾患処置用ホスホジエステラーゼ阻害剤としてのトリアゾロピリジン
PT3013814T (pt) Compostos de tetrahidrocarbazol e carbazol carboxamida substituídos úteis como inibidores de quinases
JP2017502976A (ja) １，２ナフトキノン誘導体及びその製造方法
WO2014151630A2 (fr) Composés et compositions pour le traitement de maladies parasitaires
JP7336434B2 (ja) アデノシン受容体アンタゴニストとしてのチアゾロピリジン誘導体
EP2247601A1 (fr) Thiazopyrimidinones et leurs utilisations
WO2011148956A1 (fr) Dérivé d'imidazole condensé
JP2018535261A (ja) 疾患の処置のための複素環化合物
WO2007124544A1 (fr) Inhibiteurs de l'intégrase du vih1
WO2007124545A1 (fr) Inhibiteurs d'intégrase-2
KR20100031610A (ko) 아데노신 Ａ3 수용체 리간드로서의 트리아졸로[1,5-ａ]퀴놀린
SK284387B6 (sk) Beta-karbolínové deriváty s hypnotickými účinkami, spôsob ich prípravy a liečivo s ich obsahom
CN114901642B (zh) 一种稠环化合物及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07718806

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07718806

Country of ref document: EP

Kind code of ref document: A1